Surgical technique for dogs with medially luxating patellas
Study Title: Comparison of cylindrical recession trochleoplasty (CRT) with Trochlear Block Recession (TBR) for treatment of canine medial patellar luxation
Current Status: Open and enrolling
Principal Investigators: Callie Blackford-Winders, DVM and Mike Conzemius, DVM, PhD, DACVS
Contact: Sara Pracht, Research Technician Specialist, firstname.lastname@example.org or 612-626-3574
We are studying a new technique for surgical correction of medial patellar luxation in dogs. Standard surgery involves making changes to the knee so the patella can better stay in place. The current most advanced technique uses a free-hand process to shape the knee (TBR). The new technique (CRT) uses a specialized cutting guide and blade which could prove to be more precise and to decrease the dog's pain and increase the dog's ability to move. The study is randomized and blinded, meaning one knee will receive TBR and the other CRT, and the owner will not know which knee had which treatment.
- Healthy adult dogs with medial patellar luxation in both knees
- Body weight 5-25 kg (11-55 lbs)
- No other neuromuscular or orthopedic conditions which could cause the symptoms
- Blood tests within normal limits
Dogs in the study will have standard exams for medial luxating patella, and blood collection. In addition, prior to surgery, dogs will have pressure platform gait analysis (dogs will stand or walk over a special mat) and a preoperative CT scan of both knees under general anesthesia. The standard surgery will then be performed on one knee, and the new study technique on the other knee. Dogs in the study will have a recheck visit eight weeks after the surgery for an exam, gait analysis, and X-rays of both knees under sedation.
Costs of the study:
The study will cover the costs of one knee surgery using the new technique, CT scans, gait analysis, and the recheck exam with X-rays at week eight. The owner will be responsible for the costs of the other knee surgery, hospitalization and any medications.
For more information, please contact Sara Pracht (see above).